VXRT - Vaxart Inc. Price-to-Revenue Ratio

Symbol and logo of brand Vaxart, Inc. (VXRT)

Vaxart, Inc. (VXRT) operations are strictly regulated by FDA standards for biomaterial disposal. Profit potential is based on the development of oral vaccines against influenza and norovirus. This P/S ratio chart visualizes the market valuation of revenue, where the value of 1.50 reflects this status. Ultimately, the development of this biotech firm remains independent of GDP phases, demonstrating high macro-resilience and a stable flow of investment.

Market Cap to Revenue: Vaxart Corp (VXRT) for 07/04/2022 - 07/19/2025

Metric breakdowns and analytics for Vaxart, Inc. (VXRT)

- price and consensus price forecast:
Market Chart vaxart.com|VXRT - Consensus Target
- market capitalization statistics:
Market Value Vaxart Corp|VXRT - Enterprise Value
- issuer book value statistics:
Book Value per Share Vaxart|VXRT - Company Net Assets|Capitalization to Book Value Ratio vaxart.com|VXRT - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Vaxart, Inc.|VXRT - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital vaxart.com|VXRT - Company Total Debt|Debt to Book Capital Vaxart Corp|VXRT - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Vaxart|Interim Coverage Ratio vaxart.com
- company profitability and valuation multiples indicators:
VXRT - Company Net Income|Net Profit Forecast Vaxart, Inc.|VXRT - P/E Multiple|Projected Price to Earnings vaxart.com|VXRT - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Vaxart Corp|VXRT - Operating profit before deduction of amortization|Earnings per share for the last twelve months Vaxart|VXRT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months vaxart.com|VXRT - Earnings per share growth in current year|Expected earnings per share trend next year Vaxart, Inc.
- sales revenue and business income indicators:
VXRT - Company Sales|Company Projected Revenue Volume vaxart.com|VXRT - Price-to-Revenue Ratio|Future Price to Revenue Vaxart Corp
Summary company analytics:Vaxart Inc.
Signature product of Vaxart

Developing oral vaccines within the stable environment of the US minimizes external risks, ensuring the resilience of the Vaxart, Inc. (VXRT) business model against geopolitical crises. By analyzing the historical P/S chart, an investor can see the ratio of market capitalization to annual revenue, which allows for determining the degree of overpayment for the asset and assessing the efficiency of investments relative to the company's actual operating income.

Who Vaxart, Inc. competes with

Price-to-Revenue Coefficient gilead.com|Cidara Therapeutics Inc - Market Cap to Revenue|Novavax Inc - Price-to-Revenue Ratio|CureVac Corp - P/S Multiple|VALN - P/S Multiple|VIR (Vir Biotechnology, Inc.) - Market Cap to Revenue|Market Cap to Revenue Ratio SIGA|EBS (Emergent BioSolutions Inc.) - P/S Multiple|P/S Multiple Atea Pharma|Price-to-Revenue Ratio Invivyd, Inc. (IVVD)|ENTA (Enanta Pharmaceuticals, Inc) - Market Capitalization-to-Revenue Ratio|Inovio Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume HLVX (hillevax.com)|KLRS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio DYAI (Dyadic International)|NNVC: P/S Multiple|TLPH - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Cocrystal Pharma, Inc.|Market Cap to Revenue Ratio TRAW (Traws Therapeutics)|P/S Multiple DWTX|Market Cap to Revenue Qualigen Therapeutics Inc QLGN|AlloVir - Market Cap to Revenue|Price-to-Revenue Coefficient VBI Vaccines, Inc. (VBIV)|VIRI: Market Cap to Revenue